Indications
Rinizide 300 Tablet is used for:
Tuberculosis
Adult Dose
Oral
Active Tuberculosis Disease
5 mg/kg PO qDay, not to exceed 300 mg qDay
15 mg/kg PO up; not to exceed 900 mg 1-3 times/week
Used in multi-drug regimen containing rifampin (or ribabutin or rifapentin), pyrazinamide, and ethambutol
Latent Tuberculosis Infection
Treatment of latent TB infection greatly reduces the risk that TB infection will progress to acitve disease
>30 kg: 300 mg PO qDay x9 months
Child Dose
Active Tuberculosis Disease
10-15 mg/kg PO qDay; not to exceed 300 mg/day OR
20-30 mg/kg (up to 900 mg) 2 times/week
Used in multi-drug regimen
Latent Tuberculosis Infection
Treatment of latent TB infection greatly reduces the risk that TB infection will progress to acitve disease
10-15 mg/kg PO qDay; not to exceed 300 mg/day
Renal Dose
Renal impairment: Severe: Dose reduction may be needed.
Administration
Should be taken on an empty stomach. Best taken on an empty stomach 1 hr before or 2 hr after meals. May be taken w/ meals to reduce GI discomfort.
Contra Indications
Acute liver disease or history of hepatic damage during INH therapy; hypersensitivity.
Precautions
Renal or hepatic impairment; convulsive disorders; history of psychosis; patients at risk of neuropathy or pyridoxine deficiency eg, diabetic, alcoholic, malnourished, uraemic, infected with HIV. Careful monitoring of hepatic function is necessary for black and hispanic women. Check hepatic function before and during treatment. Pregnancy and lactation.
Lactation: distributed into milk but safe for nursing infants
Pregnancy-Lactation
Interactions
Inhibit the hepatic metabolism of antiepileptics (e.g. carbamazepine, ethosuximide, primidone, phenytoin), benzodiazepines (e.g. diazepam, triazolam), chlorzoxazone, theophylline, disulfiram, sometimes leading to increased toxicity. Increased metabolism of enflurane, resulting in potentially nephrotoxic levels of fluoride. Increased concentrations and enhanced effects or toxicity of clofazimine, cycloserine and warfarin. Reduced absorption w/ Al-containing antacids. Increased risk of peripheral neuropathy w/ zalcitabine and stavudine.
Adverse Effects
Side effects of Isoniazid :
>10%
Mild incr LFTs (10-20%),Peripheral neuropathy (dose-related incidence, 10-20% incidence with 10 mg/kg/d)
Loss of appetite,Nausea,Vomiting,Stomach pain,Weakness
1-10%
Dizziness,Slurred speech,Lethargy,Progressive liver damage (increases with age; 2.3% in pts > 50 yo),Hyperreflexia
<1%
Agranulocytosis,Anemia,Megaloblastic anemia,Thrombocytopenia,Systemic lupus erythematosus,Seizure
Potentially Fatal: Hepatotoxicity.
Mechanism of Action
Isoniazid inhibits the synthesis of mycoloic acids in susceptible bacteria which results in loss of acid-fastness and disruption of bacterial cell wall. At therapeutic levels, it is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms.
Note
Rinizide 300 300mg Tablet manufactured by Lupin Ltd.. Its generic name is Isoniazid. Rinizide 300 is availble in Nepal.
Farmaco Nepal drug index information on Rinizide 300 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.